Concepts (180)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuromyelitis Optica | 19 | 2024 | 253 | 3.220 |
Why?
|
| Neurology | 4 | 2022 | 764 | 1.770 |
Why?
|
| Aquaporin 4 | 6 | 2022 | 153 | 0.960 |
Why?
|
| Remote Consultation | 3 | 2020 | 238 | 0.860 |
Why?
|
| Paresthesia | 1 | 2023 | 162 | 0.840 |
Why?
|
| Nervous System Diseases | 2 | 2022 | 1623 | 0.800 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2021 | 42 | 0.750 |
Why?
|
| Brain Death | 2 | 2021 | 348 | 0.740 |
Why?
|
| Optic Neuritis | 1 | 2022 | 166 | 0.730 |
Why?
|
| Cerebrum | 1 | 2021 | 137 | 0.690 |
Why?
|
| Telemedicine | 3 | 2022 | 2872 | 0.690 |
Why?
|
| Optic Atrophy, Hereditary, Leber | 1 | 2019 | 46 | 0.680 |
Why?
|
| Autoantibodies | 8 | 2024 | 2038 | 0.640 |
Why?
|
| Neurologic Examination | 1 | 2021 | 931 | 0.600 |
Why?
|
| Spinal Cord | 6 | 2021 | 1809 | 0.600 |
Why?
|
| Multiple Sclerosis | 7 | 2022 | 3079 | 0.590 |
Why?
|
| Agraphia | 1 | 2015 | 8 | 0.540 |
Why?
|
| Handwriting | 1 | 2015 | 28 | 0.540 |
Why?
|
| Immunity | 1 | 2021 | 1012 | 0.490 |
Why?
|
| Vision Disorders | 1 | 2019 | 1059 | 0.410 |
Why?
|
| HLA-DR Antigens | 2 | 2010 | 645 | 0.400 |
Why?
|
| Immunoglobulins, Intravenous | 3 | 2024 | 658 | 0.350 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2010 | 53 | 0.350 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2011 | 310 | 0.350 |
Why?
|
| Optic Nerve | 4 | 2021 | 556 | 0.320 |
Why?
|
| Referral and Consultation | 1 | 2021 | 3528 | 0.310 |
Why?
|
| Mycophenolic Acid | 4 | 2024 | 344 | 0.290 |
Why?
|
| Immunoglobulin G | 6 | 2020 | 4559 | 0.270 |
Why?
|
| Recovery of Function | 1 | 2015 | 2925 | 0.250 |
Why?
|
| Myasthenia Gravis | 2 | 2019 | 201 | 0.220 |
Why?
|
| Mutation, Missense | 1 | 2011 | 2563 | 0.200 |
Why?
|
| Clarithromycin | 1 | 2021 | 86 | 0.190 |
Why?
|
| Autoimmune Diseases | 2 | 2024 | 2136 | 0.190 |
Why?
|
| Plasmapheresis | 1 | 2021 | 212 | 0.180 |
Why?
|
| Restless Legs Syndrome | 1 | 2023 | 228 | 0.180 |
Why?
|
| Arm | 1 | 2023 | 590 | 0.180 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 1 | 2020 | 89 | 0.180 |
Why?
|
| Immunologic Factors | 4 | 2022 | 1582 | 0.180 |
Why?
|
| Color Vision Defects | 1 | 2019 | 28 | 0.170 |
Why?
|
| Hallucinations | 1 | 2021 | 360 | 0.160 |
Why?
|
| Scotoma | 1 | 2019 | 139 | 0.160 |
Why?
|
| Leg | 1 | 2023 | 1117 | 0.160 |
Why?
|
| Encephalitis | 1 | 2021 | 423 | 0.150 |
Why?
|
| Humans | 39 | 2024 | 744220 | 0.150 |
Why?
|
| Steroids | 1 | 2022 | 931 | 0.150 |
Why?
|
| Lyme Neuroborreliosis | 1 | 2017 | 51 | 0.140 |
Why?
|
| Orbit | 1 | 2019 | 426 | 0.140 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2018 | 236 | 0.130 |
Why?
|
| Limbic Encephalitis | 1 | 2015 | 34 | 0.130 |
Why?
|
| Paralysis | 1 | 2017 | 249 | 0.130 |
Why?
|
| Genetic Counseling | 1 | 2019 | 600 | 0.130 |
Why?
|
| Recurrence | 3 | 2024 | 8343 | 0.130 |
Why?
|
| Brain | 3 | 2020 | 26413 | 0.130 |
Why?
|
| Brain Stem | 2 | 2021 | 845 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2011 | 15525 | 0.120 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2020 | 1261 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2011 | 5442 | 0.110 |
Why?
|
| Neostriatum | 1 | 2014 | 250 | 0.110 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 1854 | 0.100 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 941 | 0.100 |
Why?
|
| Acute Disease | 1 | 2022 | 7148 | 0.100 |
Why?
|
| Tissue Donors | 1 | 2021 | 2242 | 0.100 |
Why?
|
| Heart Arrest | 1 | 2021 | 1470 | 0.090 |
Why?
|
| Female | 19 | 2024 | 380197 | 0.090 |
Why?
|
| Minnesota | 1 | 2011 | 344 | 0.090 |
Why?
|
| Visual Acuity | 1 | 2019 | 2530 | 0.090 |
Why?
|
| Medicine | 1 | 2018 | 946 | 0.090 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 12961 | 0.090 |
Why?
|
| Fibrinolytic Agents | 1 | 2020 | 2158 | 0.090 |
Why?
|
| Medication Adherence | 1 | 2021 | 2062 | 0.090 |
Why?
|
| RNA Splice Sites | 1 | 2011 | 209 | 0.090 |
Why?
|
| Middle Aged | 14 | 2022 | 213367 | 0.090 |
Why?
|
| Retrospective Studies | 8 | 2024 | 77426 | 0.090 |
Why?
|
| 5' Untranslated Regions | 1 | 2011 | 249 | 0.090 |
Why?
|
| Secondary Prevention | 3 | 2011 | 1531 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 2759 | 0.090 |
Why?
|
| 3' Untranslated Regions | 1 | 2011 | 513 | 0.080 |
Why?
|
| Disability Evaluation | 3 | 2011 | 1828 | 0.080 |
Why?
|
| Organ Specificity | 1 | 2013 | 2007 | 0.080 |
Why?
|
| Retina | 1 | 2019 | 2616 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2008 | 694 | 0.080 |
Why?
|
| Vomiting | 1 | 2010 | 635 | 0.070 |
Why?
|
| Male | 14 | 2024 | 350027 | 0.070 |
Why?
|
| Adult | 10 | 2023 | 214035 | 0.070 |
Why?
|
| Gene Frequency | 2 | 2011 | 3588 | 0.070 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2007 | 428 | 0.070 |
Why?
|
| Transplantation, Autologous | 1 | 2011 | 2124 | 0.070 |
Why?
|
| Health Expenditures | 1 | 2018 | 2348 | 0.070 |
Why?
|
| Astrocytes | 1 | 2013 | 1270 | 0.070 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 1997 | 0.070 |
Why?
|
| Treatment Outcome | 7 | 2022 | 63119 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 2 | 2021 | 7179 | 0.060 |
Why?
|
| Exons | 1 | 2011 | 2439 | 0.060 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 3509 | 0.060 |
Why?
|
| Haplotypes | 1 | 2011 | 2781 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 3871 | 0.060 |
Why?
|
| Disease Susceptibility | 1 | 2010 | 1782 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 39045 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2020 | 35423 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2011 | 21752 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3132 | 0.050 |
Why?
|
| Alleles | 2 | 2010 | 6938 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3239 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2011 | 4188 | 0.050 |
Why?
|
| Immunosuppressive Agents | 2 | 2015 | 4151 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 19907 | 0.050 |
Why?
|
| Child | 5 | 2024 | 77679 | 0.050 |
Why?
|
| Autoimmunity | 1 | 2009 | 1349 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 9275 | 0.050 |
Why?
|
| Linear Models | 1 | 2011 | 5953 | 0.050 |
Why?
|
| Disease Progression | 3 | 2024 | 13280 | 0.050 |
Why?
|
| Parkinson Disease | 1 | 2014 | 2776 | 0.040 |
Why?
|
| Electronics | 1 | 2021 | 322 | 0.040 |
Why?
|
| Hospitals, General | 1 | 2024 | 749 | 0.040 |
Why?
|
| Complement Inactivating Agents | 1 | 2019 | 50 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2009 | 2279 | 0.040 |
Why?
|
| Prednisone | 1 | 2024 | 1575 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2011 | 9849 | 0.040 |
Why?
|
| Aged | 7 | 2021 | 163253 | 0.040 |
Why?
|
| Antirheumatic Agents | 1 | 2007 | 1339 | 0.040 |
Why?
|
| Borrelia burgdorferi Group | 1 | 2017 | 97 | 0.040 |
Why?
|
| Stroke | 1 | 2020 | 9981 | 0.040 |
Why?
|
| Young Adult | 3 | 2021 | 56436 | 0.040 |
Why?
|
| New England | 1 | 2020 | 1022 | 0.040 |
Why?
|
| Rats | 1 | 2013 | 24273 | 0.040 |
Why?
|
| Complement System Proteins | 1 | 2019 | 795 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 12355 | 0.030 |
Why?
|
| Genotype | 1 | 2010 | 12956 | 0.030 |
Why?
|
| Logistic Models | 1 | 2010 | 13409 | 0.030 |
Why?
|
| Workflow | 1 | 2020 | 847 | 0.030 |
Why?
|
| Office Visits | 1 | 2018 | 598 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 950 | 0.030 |
Why?
|
| Cost Savings | 1 | 2018 | 926 | 0.030 |
Why?
|
| Phenotype | 1 | 2011 | 16365 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 15538 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2020 | 1504 | 0.030 |
Why?
|
| Animals | 4 | 2015 | 168788 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2020 | 2017 | 0.020 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 57768 | 0.020 |
Why?
|
| Dysphonia | 1 | 2014 | 144 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2020 | 2486 | 0.020 |
Why?
|
| Area Postrema | 1 | 2010 | 7 | 0.020 |
Why?
|
| Antibodies, Bacterial | 1 | 2017 | 1470 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 3176 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 2020 | 2161 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2020 | 2662 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 23337 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 17449 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 1107 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2024 | 4440 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2018 | 13990 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2020 | 53280 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 20817 | 0.020 |
Why?
|
| Receptors, Cholinergic | 1 | 2009 | 238 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2009 | 742 | 0.020 |
Why?
|
| Neurons | 1 | 2007 | 9335 | 0.020 |
Why?
|
| Blood Donors | 1 | 2009 | 355 | 0.020 |
Why?
|
| Neuromuscular Junction | 1 | 2009 | 399 | 0.020 |
Why?
|
| Mice | 1 | 2013 | 81178 | 0.020 |
Why?
|
| Massachusetts | 1 | 2018 | 8663 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 9230 | 0.020 |
Why?
|
| Brazil | 1 | 2009 | 1270 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2020 | 6150 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 6274 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 2009 | 2422 | 0.010 |
Why?
|
| Risk Factors | 1 | 2011 | 72280 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2009 | 2297 | 0.010 |
Why?
|
| Age of Onset | 1 | 2009 | 3270 | 0.010 |
Why?
|
| Age Distribution | 1 | 2009 | 2903 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2009 | 2539 | 0.010 |
Why?
|
| Medicare | 1 | 2018 | 6566 | 0.010 |
Why?
|
| Physicians | 1 | 2018 | 4564 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 4929 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8387 | 0.010 |
Why?
|
| Time Factors | 1 | 2020 | 40063 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2010 | 40992 | 0.010 |
Why?
|
| Adolescent | 3 | 2010 | 85759 | 0.010 |
Why?
|
| Comorbidity | 1 | 2009 | 10387 | 0.010 |
Why?
|
| United States | 1 | 2018 | 69867 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 18027 | 0.000 |
Why?
|
Concepts
(180)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(50)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_